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SHORT REPORT
Octapeptide repeat insertions in the prion protein gene and
early onset dementia
E A Croes, J Theuns, J J Houwing-Duistermaat, B Dermaut, K Sleegers, G Roks, M Van den Broeck,
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Objectives: The most common familial early onset dementia
mutations are found in the genes involved in Alzheimer’s
disease; the amyloid precursor protein (APP) and the
presenilin 1 and 2 (PSEN1 and 2) genes; the prion protein
gene (PRNP) may be involved.
Methods: Following identification of a two-octapeptide
repeat insertion in PRNP, we conducted a meta-analysis to
investigate the relation of number of PRNP octapeptide
repeats with age at disease onset and duration of illness;
identifying 55 patients with PRNP octapeptide repeat
insertions. We used a linear mixed effects model to assess
the relation of number of repeats with age at disease onset,
and studied the effect of the number of inserted octapeptide
repeats on disease duration with a Cox proportional hazards
regression analysis.
Results: We found an increasing number of repeats asso-
ciated with younger age at onset (p,0.001). Duration of the
disease decreased significantly with the length of the
octapeptide repeat (p,0.001) when adjusting for age at
onset.
Conclusions: Our findings show significant inverse associa-
tions of the length of the PRNP octapeptide repeat with age at
disease onset and disease duration in the spongiform
encephalopathies.
S
everal genes are known in familial early onset demen-
tias. The most common mutations are found in the
genes involved in Alzheimer’s disease. This concerns
mutations in the amyloid precursor protein (APP) and the
presenilin 1 and 2 (PSEN1 and 2) genes. Further, mutations
in the prion protein gene (PRNP) may be common in early
onset dementia.1 Mutations in PRNP may lead to different
clinical phenotypes, including familial Creutzfeldt–Jakob
disease (CJD), Gerstmann–Stra¨ussler–Scheinker disease
(GSS), and fatal familial insomnia.2–5 These mutations can
be missense mutations, deletions, or insertions.6 7 Insertions
are only found in the octapeptide repeat region located
between codons 51 and 91 of PRNP, which normally contains
one nonapeptide and four octapeptide repeats.8 The inser-
tions identified so far comprised one, two, and four to nine
extra octapeptide repeats.9 Expansion of an octapeptide
repeat or 24-nucleotide repeat region is rare, but expansion
of trinucleotide repeats are found in other neurodegenerative
disorders, including Huntington’s disease and the spinal
cerebellar ataxias.10–12 The expansion of the polyglutamine
tract in these disorders is associated with accumulation and
higher toxicity of the protein.13 For several disorders with an
expanded polyglutamine repeat an inverse correlation was
found between repeat length and age at onset.14 15 The
relation between the numbers of octapeptide repeats and
onset of disease in human spongiform encephalopathies has
not been studied.
We sequenced the coding region of APP, PSEN1, PSEN2,
and PRNP in a population based sample of 17 patients with
early onset dementia and identified in one patient an
insertion of two-octapeptide repeats. We present a meta-
analysis in which we studied the relation of the number of
inserted repeats with age at onset and duration of disease in
all patients with PRNP octapeptide repeat insertions reported
in the literature to date.
METHODS
Since 1998 we have been studying patients with early onset
dementia in a defined geographical region in the northern
part of The Netherlands. A medical doctor visited the patients
and a member of the research team and a neurologist, using a
standardised protocol based on the DSM III-R criteria,
independently confirmed the diagnosis of dementia.16 After
obtaining written informed consent from a relative, blood
was drawn for DNA collection. In this study, 17 patients with
early onset dementia were extensively studied for mutations
in genes known to be involved in dementia. Exons 16 and 17
of the APP gene, and exons 3–12 of the PSEN1 and 2 genes
were analysed by direct sequencing.17 The single coding exon
(exon 2) of PRNP was analysed by direct sequencing of three
overlapping PCR fragments (A, B, and C) spanning the
coding region.18 In one patient, visualisation of the PCR
fragments on a 1.5% agarose gel stained with ethidium
bromide demonstrated an insertion as an extra band of about
100 bp. To further characterise the insertion we cloned the
PCR fragments in the pCR4-TOPO vector (Invitrogen,
Carlsbad CA). Clones carrying the insertion were selected
by colony PCR and the insert was sequenced using vector
primers.
Meta-analysis
We used a Medline search with a combination of the words
‘‘mutation’’, ‘‘insertion’’, ‘‘octapeptide’’, or ‘‘repeats’’, and
‘‘prion’’, ‘‘PRNP’’, ‘‘Creutzfeldt–Jakob disease’’, ‘‘Gerstmann–
Stra¨ussler–Scheinker disease’’, or ‘‘spongiform encephalo-
pathy’’ to identify all patients with octapeptide repeat
insertions in the PRNP gene. We included patients suspected
of a prion disease with an octapeptide repeat extension
disclosed by DNA analysis, patients with postmortem
examination supporting the diagnosis of spongiform ence-
phalopathy and a relative with an octapeptide repeat
insertion, and patients with both postmortem examination
and DNA analysis. Patients from PRNP insertion families
Abbreviations: APP, amyloid precursor protein; CJD, Creutzfeldt–
Jakob disease; GSS, Gerstmann–Stra¨ussler–Scheinker disease; PRNP,
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suffering from an unidentified neurodegenerative disease,
without PRNP analysis or postmortem examination, were not
included.
For statistical analyses, we used the log transformed age at
onset to obtain a normally distributed outcome. A linear
mixed effects model fitted by restricted maximum likelihood
(REML) was used to assess the relation between number of
inserted octapeptide repeats and age at disease onset, and to
estimate the part of the between family variance of age at
onset explained by PRNP codon 129 and number of inserted
octapeptide repeats. Analyses were performed adjusted and
unadjusted for the PRNP codon 129 genotype. To study the
effect of the number of inserted octapeptide repeats on
disease duration we performed a Cox proportional hazards
regression analysis, adjusted for age at onset. PRNP codon
129 was not included in this model because of the limited
number of independent observations. Because we observed
an outlier in the first 6 months, analyses were performed by
conditioning on surviving the first 6 months. Robust stan-
dard errors were used that take into account dependence of
the data.
RESULTS
Mutation screening and clinical phenotype
In this sample of 17 patients with early onset dementia, we
found two mutations in genes known to be involved in
dementia. Firstly, we observed a single base change predict-
ing an amino acid change at codon 301 (T301M) in the
PSEN2 gene. The patient carrying this mutation experienced
a lack in short and long term memory just after 60 years of
age. Within a couple of years the condition of the patient
deteriorated and the patient died more than 10 years after
onset of the symptoms, with the clinical diagnosis of
Alzheimer’s dementia. The family history revealed early and
late onset dementia of unknown type in several family
members. However, in the cell transfection experiments there
is no evidence up until now that this PSEN2 mutation is
functional. The b amyloid 42/40 ratio was not altered in cells
carrying the T301M mutation compared to cells carrying the
wild type allele. Although this does not exclude the
possibility that the mutation is functional, it is unlikely, as
all functional PSEN1 and 2 mutations known to date have an
effect on the b amyloid 42/40 ratio.
The second mutation found was a two-octapeptide repeat
insert in the PRNP gene. The patient carrying this mutation
developed an atypical dementia, the age of first symptoms
being in the late 50s. In the following 10 years, the condition
of the patient slowly deteriorated into a mute state.
Myoclonus, cerebellar, and visual disturbances were absent.
Electroencephalography did not show the periodic sharp
wave complexes typical for CJD. Atypical dementia of late
onset was reported in one first degree relative.
The octapeptide repeat insertion in PRNP contained an
identical double repeated 24-nucleotide sequence located
between the fourth (normally R3) and fifth (R4) repeat and
included a silent nucleotide substitution from GGG to GGA in
the seventh triplet (coding for glycine in both cases). The
nucleotide sequence of this octapeptide repeat insertion has
been designated R2a.19 The nucleotide sequence in the third
and fourth octapeptide repeat in our patient also changed,
and was identical to that described by van Harten et al in a
patient of Dutch origin (R1 R2 R2a R2 R2a R2a R4).20 The
normal order is R1 (the nonapeptide repeat) R2 R2 R3 R4.
The patient was heterozygous for the polymorphic PRNP
codon 129, carrying the valine (V) allele on the chromosome
with the octapeptide repeat insertion, which is identical to
the disease haplotype in the patient described by Van
Harten.20
Genealogical data from our patient and the patient
described by Van Harten et al were collected using the
municipal registers. We were able to trace back the ancestors
of both patients for six generations, until 1780, but it was not
possible to link both patients to a common ancestor within
these six generations. Genealogical data were complete,
except for one branch in the fifth generation of the patient
described here, for which no information was available. The
dead end in one branch in the fifth generation, non-
paternity, or a common ancestor before 1780 may explain
our failure to establish a genealogical link.
Meta-analysis of studies of PRNP octapeptide repeat
insertions
Twenty four articles reporting PRNP octapeptide repeat
insertions in 22 different families were identified.8 9 19–40 In
total 55 patients fulfilled our inclusion criteria and had
sufficient information on clinical characteristics. Key clinical
features were a progressive dementia, ataxia, or other
cerebellar disturbances, and abnormal behaviour, mood
disorders, or other psychiatric symptoms. Table 1 shows the
age at onset, disease duration and PRNP codon 129 genotype
as described in the papers. Fig 1 gives the findings of the
meta-analysis on the association between the number of
inserted octapeptide repeats and the age at disease onset. In
this analysis, 38 patients from 17 families with information
on the PRNP codon 129 genotype were included. We found a
significant inverse relation between the number of inserted
octapeptide repeats in PRNP and age at disease onset
(p=0.0002 in the model unadjusted for PRNP codon 129
genotype and p,0.0001 after adjusting for this genotype).
Overall, the codon 129 genotype contributed significantly to
the model (p=0.0003). Compared with carriers of the PRNP
codon 129 genotype MV, patients with genotype MM tended
to have an earlier onset and carriers of genotype VV a later
onset. The PRNP codon 129 genotype and the number of
inserted octapeptide repeats in PRNP explain together 93% of
the between family variance in age at onset, leaving only 7%
unexplained.
The relation between number of repeats and survival after
disease onset was assessed in all 55 patients. Adjusted for age
at onset, survival was significantly prolonged in carriers of
the shorter repeats (p,0.001).
Finally, we extended the analyses to affected family
members (n=40) of confirmed cases, who were suspected
to carry a PRNP insert mutation on clinical grounds, but for
whom genetic analysis or a neuropathological confirmation
of CJD or GSS were not available. In this analysis, the
relation between number of PRNP repeats and age at onset
remained statistically significant (p,0.001). However, the
relation between number of PRNP repeats and survival was
no longer significant.
DISCUSSION
In this study of 17 patients with early onset dementia we
identified two carriers of mutations in genes known to be
involved in presenile dementia. One of the mutations, the
PSEN2 T301M mutation, is unlikely to be a causal mutation
given the absence of an effect on the b amyloid 42/40 levels in
cells transfected with the mutation. Further, we detected a
mutation in PRNP in one of 17 patients with early onset
dementia. The PRNP two-octapeptide repeat insertion we
observed in this patient led to an atypical form of dementia
with disease duration of more than 10 years. Repeat
insertions of two extra octapeptide repeats have been
described previously.19 20 Van Harten et al also described a
patient with a two-octapeptide repeat insertion with atypical
dementia in The Netherlands.20 We could not find a link
between the two Dutch patients within six generations.
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However, the rarity of the PRNP insertion mutations, the
presence of the V allele on the PRNP insertion haplotype, and
particularly the identical nucleotide sequence of the inserted
octapeptide repeats in both patients, suggest that the patients
are related and developed the disease as a result of the same
mutation.
Goldfarb et al described the second patient.19 This young
patient (58 years) showed a severe neurological deterioration
leading to mutism and comatose state within weeks.
However, the mother of the patient, carrying the same
mutation, showed a gradual cognitive decline at the age of 75
years leading to mutism 13 years later.19 Also, in the family
described by us there is a major difference in onset age
between the patient (late 50s) and the first degree relative
(late 70s). In the spongiform encephalopathies, the stability
of the octapeptide repeat insertions found in PRNP was
shown to be high in several generations, suggesting that a
difference in length of the inserted octapeptide repeat may
not explain the difference in onset age between first degree
relatives.34 This suggests that the disease penetrance is highly
variable and that other factors than the mutation itself may
determine the onset and progression of the disease, even in a
single family. Also the clinical features of the PRNP insert
mutations show a wide variability and range from the typical
CJD phenotype to GSS or even other neurodegenerative
disorders such as Huntington’s disease. The phenotypic
heterogeneity and late onset in some carriers may explain
also why the family history appears negative in a consider-
able number of patients. If the disease may express as late as
age 75 years, carriers may already have died of other
disorders, particularly in past centuries.
The discordance in age at onset between families of
patients carrying PRNP octapeptide repeat insertions
prompted us to perform a meta-analysis to examine the
relation between number of inserted octapeptide repeats in
PRNP and age at disease onset. Despite the large differences
found in families, we found a significant inverse relation
between number of inserted octapeptide repeats and age at
disease onset. The model including octapeptide repeat length
and PRNP codon 129 genotype explained about 93% of the
variance observed in the age at onset between the families,
leaving only 7% of the total variance unexplained, which may
either be caused by genetic or shared environmental factors,
or by random error. The meta-analysis also shows that the
10 year disease duration in our patient with two extra
octapeptide repeats is exceptional. However, the decreased
survival which is observed in carriers of shorter octapeptide
repeat insertions is, to a large extent, attributable to the older
age at onset. In the analyses taking into account the age at
onset, we found a significantly prolonged survival associated
with the shorter repeats. The duration of illness in our patient
is also compatible with the findings of Van Harten et al, who
described a disease duration of 7 years.20
Table 1 Age at disease onset, disease duration, and PRNP codon 129 genotype in
patients with PRNP octapeptide repeat insertions







Laplanche29 1 1 MM 73 4
Goldfarb19 2 2 MM 58/75 3/156+
Van Harten20 2 1 VV 61 84
This article 2 1 MV 59 120+
Laplanche29 4 1 VV 82 4
Rossi36 4 1 MM 65 6
Campbell21 4 1 MM 56 2
Yanagihara9 4 1 MM 56 5
Goldfarb26 5 2 n.a. 31/45 60/180
Cochran23 5 3 MM 26 to 44 84 to 168+
Skworc37 5 3 MV 51 to 61 4 to 96
Oda33 6 3 MM 33 to 34 60 to 84+
Capellari22 6 2 MV 38 48/120
Nicholl32 6 2 n.a. 34/46 3/60
Collinge,24 Poulter35 6 13 MM8/MV3 22 to 47 24 to 156
Goldfarb26 7 3 n.a. 23 to 35 120 to 156
Dermaut40 7 2 MM 24/31 132
Goldfarb27 8 3 MM 35 to 54 3 to 24
Laplanche30 8 5 MM 21 to 32 36 to 144+
Van Gool38 8 3 MV1/VV2 21 to 54 12+ to 72
Moore,31 Xiang421 8 4 n.a. 23 to 41 n.a.
Owen34 9 1 n.a. 53 30
Krasemann28 9 1 MM 32 72+
*Patients with mutation analysis, or patients with autopsy and a blood relative with mutation analysis, or patients
with mutation analysis as well as autopsy, are reported. M, methionine; V, valine; the numbers in superscript
denote the number of carriers. `For patients alive at time of publication, the disease duration is indicated with a
‘‘+’’ sign. 1Not included in the analyses because of missing age at onset and duration for each patient. n.a., not
available.
Figure 1 Relation between the number of insertions in the PRNP
octapeptide region and age at onset (on a log scale), adjusted for PRNP
codon 129 genotype. The best fit line is shown.
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Animal studies have shown that prion protein molecules
containing a larger octapeptide repeat region aggregate more
readily and have a higher protease resistance.41 In line with
these findings, our study suggests that longer insertions in
the octapeptide repeat region in PRNP may lead to the
inhibition of turnover resulting in a faster accumulation of
the protein, earlier onset of disease, and reduced survival.
In conclusion, in a Dutch population-based sample of 17
patients with early onset dementia, we identified one patient
in whom the disease was most likely explained by a two-
octapeptide repeat insertion in PRNP. We further showed in a
meta-analysis that the number of inserted octapeptide
repeats in PRNP is inversely related to age at onset and
duration of disease. Our meta-analysis shows that the length
of the octapeptide repeat insertion in combination with the
PRNP codon 129 genotype explains a large part of the
variation in age at onset observed. The challenge in the future
will be to determine the biological mechanism underlying
this process.
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Unusual differential diagnosis of leptomeningeal enhancement: moyamoya disease
W
e report on a 13 year old boy
who presented with a focal left
sided motoric seizure and a
history of progressive headaches since 6
years of age. On neurological examina-
tion, motor function of the limbs, deep
tendon reflexes, and sensory examination
were normal, but there was slight left
sided bradydisdiadochokinesis. Routine
blood tests and anti-immune antibody
screening as well as cerebrospinal fluid
(CSF) analysis were normal.
Magnetic resonance imaging (MRI)
showed multiple curvilinear areas of
high signal intensity in leptomeninges
(fig 1A) and diffuse enhancement along
leptomeningeal surfaces (fig 1B). Digital
subtraction angiography demonstrated
severe stenoses of both distal internal
carotid artery (ICA) segments (fig 1C)
as well as extensive leptomeningeal
collaterals (fig 1D).
Leptomenigeal enhancement on post-
contrast T1 weighted MR images has
been reported in association with
meningitis, meningeal carcinomatosis,
and angiitis. Common among these
diseases is pathologic inflammation or
carcinomatous infiltration of the lepto-
meninges, with or without involvement
of the small leptomeningeal vessels.
In 1995 Ohta et al1 reported diffuse
leptomeningeal enhancement on post-
contrast T1 weighted MRI in children
with moyamoya disease and named
these finding the ‘‘ivy-sign’’, because it
resembles ivy creeping on stones. The
ivy-sign can be found on fluid attenua-
tion inversion recovery (FLAIR) images,
as well as on contrast enhanced MRI.2 3
The characteristic enhancement is
caused by an engorged pial network
via leptomeningeal anastomosis. The
source of leptomeningeal high signal
intensity on FLAIR images is not clear
but it seems largely due to slow flowing
vessels of the engorged pial network.2
Thus, the mechanism of the leptome-
ningeal ivy-sign can be explained by an
engorged pial network and possibly the
congested meninges.
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Figure 1 (A) Axial FLAIR MRI reveals multiple areas of high signal intensity (arrows) in
leptomeninges. (B) Axial contrast enhanced T1 weighted image shows diffuse enhancement along
leptomeningeal surfaces (arrows). (C) Lateral view of right carotid angiogram and (D) right
vertebral angiogram demonstrate severe stenoses at the distal ICA (arrow) and wide terminal
segments of the posterior and middle cerebral arteries due to extensive leptomeningeal collateral
flow (arrowheads).
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